CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-03 | Dandekar Atul CSBO | Sale | −3,207 | $26.01 | $83K | 32,352 |
| 2026-09-03 | Dandekar Atul CSBO | Sale | −36 | $25.81 | $929 | 32,316 |
| 2026-09-03 | Courtney Phillips GC and Corp. Secretary | Sale | −1,990 | $26.01 | $52K | 7,029 |
| 2026-09-03 | Courtney Phillips GC and Corp. Secretary | Sale | −22 | $25.78 | $567 | 7,007 |
| 2026-09-03 | Coloma Jason V Chief Executive Officer | Sale | −11,282 | $26.01 | $293K | 27,491 |
| 2026-09-03 | Coloma Jason V Chief Executive Officer | Sale | −129 | $25.77 | $3K | 27,362 |
| 2026-09-02 | Bernstein Harold President, R&D & CMO | Sale | −4,481 | $26.38 | $118K | 15,519 |
| 2026-09-02 | Bernstein Harold President, R&D & CMO | Sale | −625 | $27.12 | $17K | 14,894 |
| 2026-09-02 | Dandekar Atul CSBO | Sale | −2,800 | $26.38 | $74K | 35,950 |
| 2026-09-02 | Dandekar Atul CSBO | Sale | −391 | $27.12 | $11K | 35,559 |
| 2026-09-02 | Courtney Phillips GC and Corp. Secretary | Sale | −1,738 | $26.38 | $46K | 9,262 |
| 2026-09-02 | Courtney Phillips GC and Corp. Secretary | Sale | −243 | $27.12 | $7K | 9,019 |
| 2026-09-02 | Coloma Jason V Chief Executive Officer | Sale | −9,852 | $26.38 | $260K | 40,148 |
| 2026-09-02 | Coloma Jason V Chief Executive Officer | Sale | −1,375 | $27.12 | $37K | 38,773 |
| 2026-09-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +16,141 | $10.42 | $168K | 16,141 |
| 2026-09-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −16,141 | $26.36 | $426K | 0 |
| 2026-09-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +20,000 | 20,000 | ||
| 2026-09-01 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,141 | 160,662 | ||
| 2026-09-01 | Bernstein Harold President, R&D & CMO | Option exercise · Restricted Stock Units 10b5-1 | −20,000 | 20,000 | ||
| 2026-09-01 | Dandekar Atul CSBO | Option exercise | +12,500 | 38,750 |
Page 2 of 14 · 267 trades